Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953792 | 0.89 | RAB9A (0.61) | NPC1RAB9AHTR1AHTR2AHTR7 | |
| SCHEMBL4949410 | 0.86 | FKBP1A (0.52) | RAB9AHTR1AHTR2AHTR7HTR6 | |
| SCHEMBL4951152 | 0.86 | HTR1A (0.55) | RAB9AHTR1AHTR2AHTR7HTR6 | |
| SCHEMBL4948828 | 0.85 | ENPP2 (0.49) | HTR1AHTR2AHTR7HTR6PDK2 | |
| SCHEMBL4952558 | 0.85 | FKBP1A (0.56) | HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL4955662 | 0.85 | NPC1 (0.60) | NPC1RAB9AHPGD | |
| SCHEMBL4954896 | 0.85 | ENPP2 (0.50) | HTR1AHTR2AHTR7HTR6HPGD | |
| SCHEMBL13996781 | 0.84 | RAB9A (0.58) | NPC1RAB9APDK2GHSRHPGD | |
| SCHEMBL4953282 | 0.83 | HTR1A (0.46) | HTR1AHTR2AHTR7HTR6GHSR | |
| SCHEMBL4951646 | 0.83 | MEN1 (0.58) | HTR1AHTR2AHTR7HTR6GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | ATF4 1751/4885NPC1 313/4885RAB9A 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.